Prognostic Biomarkers for Papillary Thyroid Cancer: Reducing Overtreatment, Improving Clinical Efficiency, and Enhancing Patient Experience.

Papillary thyroid cancer (PTC), the most prevalent form of thyroid malignancy, is generally indolent but poses a recurrence risk of 10%-15%, leading to a clinical paradox: the need to mitigate recurrence while avoiding overtreatment. Current prognostic frameworks, reliant on anatomical and histopathological factors, often result in inefficient treatment pathways, unnecessary surgical interventions, and increased patient burden. The advent of molecular diagnostics presents a paradigm shift in risk stratification. Implementing preoperative molecular tests could transform PTC management by enabling tailored therapeutic strategies, reducing the need for completion thyroidectomies, optimizing the selection of patients for active surveillance, and refining the use of adjuvant therapies such as radioactive iodine. While genomic alterations such as BRAF and TERT mutations have been explored as prognostic markers, their predictive utility remains limited. In contrast, transcriptomic profiling has emerged as a powerful tool for identifying aggressive PTC subtypes with greater precision. Transcriptomic-based prognostic tests, like the novel Thyroid GuidePx^® classifier, effectively stratify PTCs into distinct molecular subgroups with differing recurrence risks, surpassing traditional clinicopathological models in predictive accuracy. By shifting toward biologically informed decision-making, we can enhance clinical efficiency, minimize patient morbidity, and improve overall healthcare resource utilization.